Tumor necrosis factor (TNF) inhibitor drugs target the TNF protein responsible for triggering inflammation as part of several disease processes in the human body that are part of the pathophysiology of inflammatory bowel diseases, rheumatologic joint conditions, and psoriasis. Examples of TNF inhibitors approved by the US Food and Drug Administration for these conditions include adalimumab, certolizumab, etanercept, golimumab, and infliximab. These agents can be used as monotherapy or in combination with other medications (eg, methotrexate, prednisone, leflunomide, hydroxychloroquine, sulfasalazine). They are specifically designed to treat inflammatory conditions, and can be administered by subcutaneous injection — weekly, every other week, or every 4 weeks — or by an intravenous infusion every 4-8 weeks.
Are you aware of the most recent research into TNF inhibitors and their indications, efficacy, and adverse effects? Take this short quiz to find out.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Rapid Rx Quiz: TNF Inhibitors - Medscape - Oct 20, 2023.
Comments